gainbot
BriefMoversScreensSectorsEarningsIPOsNewsDividends & splitsScreenerWatchlistLearn
NASDAQ · LUCDHealthcareSurgical Instruments

Lucid Diagnostics Inc. Common Stock (LUCD)

$0.4451+8.83%
Close Nov 4, 2026 · split-adjusted
Nov 4, 2026$0.45▼ 59.11% in range
Nov 4, 2025Low $0.33 · High $1.47Nov 4, 2026
What changed · written from our data
As of Nov 4, 2026

Lucid Diagnostics closed at $0.45 on Nov 4, up 8.83%, 69.7% below its 52-week closing high. Volume of 3.6M shares was 0.27× its 20-day average (below normal).

Split-adjusted performance: -25.8% over one month, -58.8% over six months, -63.2% over one year.

In the quarter ended Jun 30, 2026, revenue was $1.47M, up 26.7% from a year earlier, with a net margin of -998.3%.

Short interest was 13.6M shares at the Oct 15 settlement, up 1.3% from the prior report (8.7% of float, 5.8 days to cover).

Market cap$85.0M190.9M shares
Revenue · quarter$1.5M+26.7% YoY
Diluted EPS$-0.08—
P/E · TTM—P/S 15.6×
Net margin-998.3%Gross 2.0%
Dividend yieldNone
52-week range0.33 – 1.47−69.7% from high
Volume3.6M0.27× 20-day avg
Volatility · 60d109.9%Annualised
Short % of float8.7%5.8 days to cover
Net cash$9.9MCash $33.4M
Next earnings—Not scheduled
Split-adjusted performance
1W +8.1%1M −25.8%3M −53.3%6M −58.8%YTD −59.2%1Y −63.2%3Y −65.5%5Y −95.2%

Earnings reactions

History →

No reported quarters with price history yet.

Rank within Surgical Instruments

Percentile among 110 companies (100 = best)

6-month momentum18
Revenue growth83
Net margin6
Value (low P/E)—
Size38

Industry medians: 6-month return −4.0%, revenue growth +8.9%, net margin −8.2%, P/E 30.5×.

Short interest

Details →
Shares short13.6M+1.3% vs prior
Days to cover5.8Settled Oct 15
% of float8.7%
Short vol. 10d59.5%of daily volume

Closest peers by size in Surgical Instruments

CompanyPriceToday6MRev. growthNet marginP/EMkt cap
LUCDLucid Diagnostics$0.4451+8.83%−58.8%+26.7%−998.3%—$85.0M
MBOTMicrobot Medical$1.14+4.59%−47.9%—−2334.9%—$76.6MCompare
SKINSkinHealth Systems$11.05+6.76%−40.8%−7.8%−3.7%—$72.0MCompare
LNSRLENSAR$5.84+4.85%+8.4%+18.4%10.7%4.6$71.7MCompare
APYXApyx Medical$2.59−0.38%−11.3%+22.1%−23.4%—$109.1MCompare
LUNGPulmonx$2.83+4.04%+119.4%−4.6%−44.3%—$121.5MCompare
SRTSSensus Healthcare$3.25−1.07%−20.5%−68.7%−382.1%—$53.5MCompare
DXRDaxor$8.91+2.44%−12.1%+2.3%−403.2%—$52.0MCompare
SNWVSANUWAVE Health$5.73−3.37%−64.0%−3.1%−7.0%3.4$49.3MCompare

News about Lucid Diagnostics

All news →
Lucid Diagnostics to Hold Fourth Quarter and Full Year 2025 Business Update Conference Call and Webcast on March 26, 2026Benzinga · Mar 12, 2026Neutral

Quick answers

What does Lucid Diagnostics do?
Lucid Diagnostics Inc is a commercial-stage medical diagnostics technology company focused on the millions of patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically lethal esophageal adenocarcinoma. Its products include EsoCheck and EsoGuard.
What is LUCD's market cap?
$84.99M, based on the Nov 4 close of $0.45.
Does Lucid Diagnostics pay a dividend?
No regular cash dividend has been paid in the last year.
How much of LUCD is sold short?
13.6M shares, 8.7% of float, as of Oct 15, 2026.
What sector is LUCD in?
Healthcare, in the Surgical Instruments industry.

About Lucid Diagnostics

Lucid Diagnostics Inc is a commercial-stage medical diagnostics technology company focused on the millions of patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically lethal esophageal adenocarcinoma. Its products include EsoCheck and EsoGuard.

HQ: New York, NY82 employeesListed Oct 14, 2021luciddx.com

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology